Business Context and Reporting Period
Syndax Pharmaceuticals, Inc. (SNDX) filed this Form 8-K on December 14, 2023, to report the entry into a material definitive agreement. The company is a Delaware corporation headquartered in Waltham, Massachusetts, focused on pharmaceutical development.
Key Financial Metrics and Transaction Details
This filing details a public offering of common stock rather than periodic financial performance metrics. Key transaction figures include:
- Shares Issued: 10,810,810 shares of Common Stock.
- Offering Price: $18.50 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to 1,621,621 additional shares.
- Gross Proceeds: Approximately $200.0 million, or approximately $230.0 million if the over-allotment option is fully exercised.
- Underwriters: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Cowen and Company, LLC.
- Expected Closing: On or about December 19, 2023.
The filing text does not provide current revenue, profit, cash flow, margins, or debt levels; these metrics are not applicable to this specific current report.
Material Changes and Lock-Up Provisions
The primary material change is the dilution of existing shareholders due to the issuance of new shares and the influx of capital. To support the offering, the Company, its directors, executive officers, and certain stockholders have agreed to a 60-day lock-up period, prohibiting the sale or transfer of Common Stock without written consent from Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC.
Outlook, Risks, and Contingencies
The offering is subject to customary closing conditions. The Underwriting Agreement includes standard representations, warranties, covenants, and indemnification obligations. The filing notes that the description of the agreement is qualified by reference to the full Underwriting Agreement attached as Exhibit 1.1. No specific operational risks or contingencies beyond standard underwriting terms are detailed in this summary text.
Investor Verification Checklist
- Verify the final closing date and whether the underwriters exercised the over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification details.
- Confirm the net proceeds after deducting underwriting discounts, commissions, and offering expenses.
- Monitor the 60-day lock-up expiration date for potential selling pressure from insiders.